Citius Pharmaceuticals (CTXR) Stock Price, Quote, News & History | Benzinga

Citius Pharmaceuticals Inc (CTXR) Stock Price, Quote, News & History

CTXRNASDAQ

Trade with Public

Trade with Public

$0.6021

-0.0269-4.28%

At close: Aug 28, 5:00 PM EST

$0.6050

0.00290.48%

After Hours: Aug 28, 6:17 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$0.62

Close

$0.60

Volume / Avg.

361.74K / 569.78K

Day Range

$0.59 - $0.63

52 Wk Range

0.47 - 2.19

Market Cap

$16.61M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

49

Short Interest

19.91%

Days to Cover

5.32

Recent Citius Pharmaceuticals Inc News

What's Behind The Drop In Citius Pharmaceuticals?

Citius Pharmaceuticals (NASDAQ:CTXR) shares tumbled on Friday after it announced a registered direct offering, raising dilution concerns.

Alex Perry

Gold Edges Lower; Omeros Shares Jump

Avi Kapoor

Dow Gains Over 100 Points; US Jobless Claims Decline

Avi Kapoor

Stock Market Today: Dow Jones, Nasdaq Futures Slip On Christmas Eve Despite Strong Q3 GDP Report— UiPath, AST SpaceMobile, Ramaco In Focus (UPDATED)

(Editor’s note: The future prices of benchmark tracking ETFs and headline were updated in the story.) U.S. stock futures slipped on Wednesday after Tuesday’s higher close. Futures of major benchmark indices fell.

Rishabh Mishra

Citius Pharmaceuticals (CTXR) Surges 22% After Hours — Here's Why

Citius Pharmaceuticals shares jumped 22.12% after hours following the commercial launch of its LYMPHIR therapy and a fiscal 2025 business update.

Mohd Haider

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-34.87M

Investing Cash Flow (TTM)

-12.75M

Financing Cash Flow (TTM)

58.54M

Free Cash Flow (TTM)

-34.87M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

10.92M

Analyst Trends and Forecast

1

Mar

1

May

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$6.70M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

1.93

PB Ratio (TTM)

0.26

Earnings Yield % (TTM)

-278.22%

Earnings Yield % (FWD)

-228.93%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.43

Company Debt

Total Debt

$6.41M

LT Debt

$6.41M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$17.01M

Debt to Equity

0.11

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$0.62

Close

$0.60

Volume / Avg.

361.74K / 569.78K

Day Range

$0.59 - $0.63

52 Wk Range

0.47 - 2.19

Market Cap

$16.61M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

49

Short Interest

19.91%

Days to Cover

5.32

About

Sector

Health Care

Industry

Pharmaceuticals

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Citius Pharmaceuticals (CTXR) stock?

A

You can purchase shares of Citius Pharmaceuticals (NASDAQ:CTXR) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Citius Pharmaceuticals (CTXR) competitors?

A

Other companies in Citius Pharmaceuticals’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).

Q

What is the forecast, or price target, for Citius Pharmaceuticals (CTXR) stock?

A

Citius Pharmaceuticals has a consensus price target of $5.00.

Q

What is the current price for Citius Pharmaceuticals (CTXR)?

A

The stock price for Citius Pharmaceuticals (NASDAQ: CTXR) is $0.605 last updated August 28, 2026 at 6:17 PM EDT.

Q

Does Citius Pharmaceuticals (CTXR) pay a dividend?

A

There are no upcoming dividends for Citius Pharmaceuticals.

Q

When is Citius Pharmaceuticals (NASDAQ:CTXR) reporting earnings?

A

Citius Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Citius Pharmaceuticals (CTXR) going to split?

A

There is no upcoming split for Citius Pharmaceuticals.

Q

What sector and industry does Citius Pharmaceuticals (CTXR) operate in?

A

Citius Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.